Novartis scoops up IFM immunotherapy subsidiary for $310 million

Pharmaceutical giant Novartis will pay $310 million to purchase an Atlas Venture-backed Boston startup focused on treatments using the body's immune system. Novartis (NYSE: NVS) has signed a deal to purchase pre-commercial company IFM Tre. Another $1.27 billion will be available in milestone payments, bringing the deal total to nearly $1.6 billion, according to a press release. IFM Tre launched in July 2018 with plans to develop therapies for inflam matory diseases that block the production of…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news